Defence And Security Tenders

Market Research - Launching an Index Fund with Corporate Bonds

Passenger Transport Services in Line Bundles 8 and 9 of the Znas

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Clonazepam, Atc N03ae01 (Obg) for the Period August 1St, 2024 - July 31St, 2026

In-House Award of a Public Service Contract for Public Transport Services in a Group of Routes

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Olanzapine (Excl. Dafo. for the Production of a Depot - Isu, Atc N05ah03 (Obo) F. 01.08.24 - 31.07.26

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Lisdexamfetamine, Atc N06ba12 (Obg) for the Period August 1, 2024 - July 31, 25 (Plus Extension Option 1X12 Months)

Medicines with the Active Ingredient Ustekinumab (Atc: L04ac05)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Albendazole, Atc P02ca03 (Obg) for the Period August 1St, 2024 - July 31St, 2026

Medicines with the Active Ingredient Lanthanum (Iii) Carbonate (Atc: V03ae03 - in the Dosage Form Chewable Tablets)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Naloxegol, Atc A06ah03 (Obo) for the Period August 1St, 2024 - July 31St, 2026